ASX - By Stock
|
PER |
Re:
For General Information
|
|
sankaido
|
3.5K |
1.0M |
10 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
10
|
|
ASX - By Stock
|
PER |
Re:
Combo Data
|
|
sankaido
|
99 |
28K |
3 |
11/11/22 |
11/11/22 |
ASX - By Stock
|
99
|
28K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Combo Data
|
|
sankaido
|
99 |
28K |
1 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
99
|
28K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Combo Data
|
|
sankaido
|
99 |
28K |
2 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
99
|
28K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Combo Data
|
|
sankaido
|
99 |
28K |
0 |
08/11/22 |
08/11/22 |
ASX - By Stock
|
99
|
28K
|
0
|
|
Charts
|
PER |
Re:
Chart
|
|
sankaido
|
5.9K |
2.3M |
6 |
22/09/22 |
22/09/22 |
Charts
|
5.9K
|
2.3M
|
6
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
2 |
25/10/21 |
25/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
0 |
22/10/21 |
22/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
0
|
|
Charts
|
PER |
Re:
Chart
|
|
sankaido
|
5.9K |
2.3M |
4 |
21/10/21 |
21/10/21 |
Charts
|
5.9K
|
2.3M
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
sankaido
|
5.9K |
2.3M |
3 |
20/10/21 |
20/10/21 |
Charts
|
5.9K
|
2.3M
|
3
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
4 |
18/10/21 |
18/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
3 |
18/10/21 |
18/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
1 |
18/10/21 |
18/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
0 |
16/10/21 |
16/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
7 |
16/10/21 |
16/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
1 |
15/10/21 |
15/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
10 |
14/10/21 |
14/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
9 |
06/10/21 |
06/10/21 |
ASX - By Stock
|
1.0K
|
373K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
1 |
16/09/21 |
16/09/21 |
ASX - By Stock
|
1.0K
|
373K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
0 |
15/09/21 |
15/09/21 |
ASX - By Stock
|
1.0K
|
373K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
0 |
14/09/21 |
14/09/21 |
ASX - By Stock
|
1.0K
|
373K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
6 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
1.0K
|
373K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to participate in development of DMD Guidance for FDA
|
|
sankaido
|
6 |
2.9K |
4 |
25/08/21 |
25/08/21 |
ASX - By Stock
|
6
|
2.9K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
4 |
09/07/21 |
09/07/21 |
ASX - By Stock
|
1.0K
|
373K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
3 |
02/07/21 |
02/07/21 |
ASX - By Stock
|
1.0K
|
373K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
|
|
sankaido
|
57 |
21K |
2 |
27/06/21 |
27/06/21 |
ASX - By Stock
|
57
|
21K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
|
|
sankaido
|
57 |
21K |
2 |
27/06/21 |
27/06/21 |
ASX - By Stock
|
57
|
21K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
|
|
sankaido
|
57 |
21K |
9 |
27/06/21 |
27/06/21 |
ASX - By Stock
|
57
|
21K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
5 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
1.0K
|
373K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
|
|
sankaido
|
57 |
21K |
3 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
57
|
21K
|
3
|
|
ASX - By Stock
|
PER |
Re:
DMD Gene Therapy - Pfizer Inc
|
|
sankaido
|
19 |
7.2K |
13 |
16/06/21 |
16/06/21 |
ASX - By Stock
|
19
|
7.2K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
sankaido
|
191 |
60K |
6 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
191
|
60K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
1 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
1.0K
|
373K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
3 |
31/05/21 |
31/05/21 |
ASX - By Stock
|
1.0K
|
373K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
4 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
1.0K
|
373K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
7 |
25/05/21 |
25/05/21 |
ASX - By Stock
|
1.0K
|
373K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
sankaido
|
1.0K |
373K |
7 |
24/05/21 |
24/05/21 |
ASX - By Stock
|
1.0K
|
373K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Type C Meeting for ATL1102 in DMD
|
|
sankaido
|
87 |
34K |
15 |
03/05/21 |
03/05/21 |
ASX - By Stock
|
87
|
34K
|
15
|
|
ASX - By Stock
|
PER |
Re:
US deal for ATL1102
|
|
sankaido
|
202 |
74K |
7 |
21/04/21 |
21/04/21 |
ASX - By Stock
|
202
|
74K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics appoints new Non-Executive Director
|
|
sankaido
|
37 |
13K |
4 |
22/03/21 |
22/03/21 |
ASX - By Stock
|
37
|
13K
|
4
|
|
ASX - By Stock
|
PER |
Re:
ATL1102 Antisense and Multiple Sclerosis
|
|
sankaido
|
3 |
2.3K |
8 |
25/01/21 |
25/01/21 |
ASX - By Stock
|
3
|
2.3K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Fda guidance for DMD drugs
|
|
sankaido
|
27 |
8.0K |
0 |
08/10/20 |
08/10/20 |
ASX - By Stock
|
27
|
8.0K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Fda guidance for DMD drugs
|
|
sankaido
|
27 |
8.0K |
2 |
08/10/20 |
08/10/20 |
ASX - By Stock
|
27
|
8.0K
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
sankaido
|
5.9K |
2.3M |
0 |
24/09/20 |
24/09/20 |
Charts
|
5.9K
|
2.3M
|
0
|
|
ASX - By Stock
|
PER |
Re:
Video Summary on the PPMD Website
|
|
sankaido
|
44 |
12K |
3 |
23/07/20 |
23/07/20 |
ASX - By Stock
|
44
|
12K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Video Interview with Mark Diamond
|
|
sankaido
|
39 |
9.4K |
1 |
03/07/20 |
03/07/20 |
ASX - By Stock
|
39
|
9.4K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Video Interview with Mark Diamond
|
|
sankaido
|
39 |
9.4K |
1 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
39
|
9.4K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Video Interview with Mark Diamond
|
|
sankaido
|
39 |
9.4K |
3 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
39
|
9.4K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Video Interview with Mark Diamond
|
|
sankaido
|
39 |
9.4K |
14 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
39
|
9.4K
|
14
|
|
ASX - By Stock
|
PER |
Re:
Video Interview with Mark Diamond
|
|
sankaido
|
39 |
9.4K |
0 |
02/07/20 |
02/07/20 |
ASX - By Stock
|
39
|
9.4K
|
0
|
|